Continuous treat-to-target ULT superior to discontinuation for gout remission: GO TEST FINALE
The 2-year GO-TEST FINALE trial demonstrated that continued urate-lowering therapy (ULT) using a treat-to-target strategy was superior to ULT discontinuation attempts for maintaining gout remission. Continued therapy was associated with fewer flares, lower anti-inflammatory medication use, and a smaller decline in kidney function over 24 months.